Vaccines against tularemia
The disclosure relates generally to an antigenic composition useful for immunization against tularemia. The disclosure is a method for producing a vaccine for preventing tularemia in humans and animals, a new vaccine against tularemia in humans and animals, and a new approach to producing vaccines against tularemia.
1. A live attenuated vaccine comprising an F. tularensis lacking a polynucleotide encoding CapB, (LVSΔcapB), and wherein the F. tularensis over-expresses an F. tularensis antigen selected from the group consisting of IglA, IglC and a combination thereof.
2. The live attenuated vaccine of claim 1 , wherein the LVSΔcapB overexpresses an immunogenic IglC.
3. The live attenuated vaccine of claim 1 , wherein the LVSΔcapB overexpresses an immunogenic IglA.
4. The live attenuated vaccine of claim 1 , wherein the LVSΔcapB overexpresses an immunogenic IglA and IglC.
5. An immunogenic composition comprising a live attenuated vaccine of claim 1 useful for inducing an immune response against Francisella tularensis , said antigen comprising an extracellular or immunogenic polypeptide of F. tularensis IglA, IglC or a combination thereof linked to transcriptional promoter and termination signals.
6. The immunogenic composition of claim 5 , further comprising a pharmaceutical diluent.
7. The immunogenic of claim 5 , wherein the antigen comprises a sequence selected from the group consisting of SEQ ID NO: 12 and 22 and any combination of the foregoing.
8. A recombinant attenuated F. tularensis lacking a polynucleotide encoding CapB, LVSΔcapB and comprising a polynucleotide encoding at least one extracellular or immunogenic protein of F. tularensis selected from the group consisting of IglA, IglC and a combination thereof, wherein the polynucleotide encoding IglA, IglC and a combination thereof is overexpressed and that induces a immunity against F. tularensis.
9. A method of inducing immunity in a subject comprising administering the composition of claim 5 to the subject.
10. A method of immunizing a susceptible host against an infection of Francisella tularensis comprising administering to said host an amount of the immunogenic composition of claim 5 sufficient to invoke an immune response in the host.
11. The method of claim 10 , wherein the composition is in a pharmaceutically acceptable carrier.
12. A method of inducing immunity in a subject comprising administering the live attenuated vaccine of claim 1 .